Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Value-Based Cancer Care

- PMLiVE

FDA approves Mirum’s Livmarli to treat cholestatic pruritus in rare liver disease patients

Progressive familial intrahepatic cholestasis affects one in every 50,000 to 100,000 births in the US and Europe

- PMLiVE

UKHSA and The Pirbright Institute collaborate to develop vaccines against henipaviruses

There are currently no licensed vaccines or treatments for the Nipah virus

- PMLiVE

Study reveals molecular signatures driving immune cell attacks in chronic neurological diseases

MS is a chronic neurological disease that affects more than two million people worldwide

- PMLiVE

New syndicated report – Living with Ulcerative Colitis 2024

Living with Ulcerative Colitis (UC) is a new syndicated patient report that presents valuable insights into the unmet needs and the burden experienced by patients living with UC. The report...

Research Partnership

Navigating Regulatory Challenges – Top 10 Most Important Advisor Questions

This quick video covers #9 of our Top 10 Most Important Advisor Questions, shedding light on the complexities of local and national regulatory issues in the Pharma and Life Sciences...

Impetus Digital

- PMLiVE

AstraZeneca expands rare disease pipeline with $1.05bn Amolyt Pharma acquisition

The deal gives the company access to a late-stage candidate being evaluated for hypoparathyroidism

- PMLiVE

Pfizer’s Adcetris combination shows promise in phase 3 large B-cell lymphoma study

The aggressive blood cancer affects more than 25,000 people in the US every year

regeneron headquarters

Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol

Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment

- PMLiVE

Dermavant reports positive late-stage results for Vtama cream in atopic dermatitis

The inflammatory skin disease affects up to 10% of adults and 20% of children worldwide

- PMLiVE

How is the vaccine reimbursement environment changing?

By Claire Woon

AMICULUM

- PMLiVE

Transforming San Diego for AAD 2024

The 2024 meeting of the American Academy of Dermatology has wrapped up, and Medscape has returned from a series of successful days at their booth, symposia, and offsite event. To...

Medscape Education Global

- PMLiVE

Almirall gains rights to Eloxx’s rare dermatological disease asset in deal worth over $470m

ZKN-013 is designed to overcome nonsense mutations in rare skin diseases such as junctional epidermolysis bullosa

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links